<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106869</url>
  </required_header>
  <id_info>
    <org_study_id>Venti-delirium</org_study_id>
    <nct_id>NCT04106869</nct_id>
  </id_info>
  <brief_title>The Influence of Ventilation on Perioperative Neurocognitive Disorders</brief_title>
  <official_title>Does Intra-operative Low End Tidal CO2 Aggravate Perioperative Neurocognitive Disorders?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Libre de Bruxelles</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study is designed to examine the influence of intra-operative ventilation on&#xD;
      perioperative neurocognitive disorders in patients undergoing total hip arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative neurocognitive disorders (PND's) remain an important complication after&#xD;
      surgery. After many years of speculating about the etiology of this complication, currently&#xD;
      studies are pointing to an inflammatory cascade being set in motion. Following the&#xD;
      combination of surgery/ anesthesia, high molecular group box protein 1 (HMGB1) is released.&#xD;
      This damage-associated molecular pattern (DAMP) binds to pattern recognition receptors (PRR)&#xD;
      on circulating bone marrow-derived monocytes (BM-DMs). Through an intracellular signaling&#xD;
      pathway, the transcription factor NF-kappa B passes into the nucleus, is activated and&#xD;
      increases expression and release of pro-inflammatory cytokines. These in turn disrupt the&#xD;
      blood brain barrier. Within the brain parenchyma the chemokine monocyte chemoattractant&#xD;
      protein 1 (MCP-1) is upregulated and attracts the BM-DMs through binding to its receptor,&#xD;
      CCR2. In turn, this activates the resident quiescent microglia. Together, the BM-DMs and&#xD;
      activated microglia release HMGB1 and pro-inflammatory cytokines that disrupt long-term&#xD;
      potentiation (LTP) thereby blocking synaptic plasticity changes that are required for the&#xD;
      cognitive functions of learning and memory.&#xD;
&#xD;
      Optimizing intraoperative ventilation has been the goal of many studies, which have suggested&#xD;
      obtaining protective ventilation through the use of low tidal volumes (6-8 ml/kg) and driving&#xD;
      pressure below 15 mm Hg.&#xD;
&#xD;
      Very few articles have focused on the influence of intra-operative ventilatory management on&#xD;
      PND's.&#xD;
&#xD;
      This prospective study is designed to examine the influence of intra-operative ventilation on&#xD;
      perioperative neurocognitive disorders in patients undergoing total hip arthroplasty.&#xD;
&#xD;
      The objectives in our study are to:&#xD;
&#xD;
      Evaluate the influence of intra-operative ventilation on the incidence of incidence and&#xD;
      duration of perioperative neurocognitive disorders in a known high-risk group of surgical&#xD;
      patients.&#xD;
&#xD;
      Measure peripheral inflammatory markers (IL-6) in the same group of surgical patients.&#xD;
&#xD;
      The evaluation of the presence of peri-operative neurocognitive disorders in patients&#xD;
      scheduled for a total hip arthroplasty will be done by using the T-MOCA test. Patients will&#xD;
      have to take this test at three time-points (Baseline, 6 weeks post-operatively and 3 months&#xD;
      post-operatively.) Patients will be randomized to two groups. One group will be ventilated to&#xD;
      obtain intra-operative end-tidal CO2 below 35 mm Hg and the other group will be ventilated to&#xD;
      obtain intra-operative end-tidal CO2 of 40-45 mm Hg. Peripheral inflammatory markers will as&#xD;
      well be measured in the same group of patients.&#xD;
&#xD;
      Anesthesia management of these patients will comply to our hospital's standard of care&#xD;
      practice.&#xD;
&#xD;
      Monitoring of Physiological Parameters During General Anesthesia: Heart rate, oxygen&#xD;
      saturation (SpO2), respiratory rate, non-invasive blood pressure, end-tidal CO2 levels,&#xD;
      inspired/end-tidal O2 levels, inspired/end-tidal sevoflurane concentrations, and temperature&#xD;
      will be continuously monitored and recorded throughout the surgical procedure, to ensure that&#xD;
      the measured physiological parameters are within the normal range.&#xD;
&#xD;
      Similarly, the cumulative doses of all sedative and analgesic medications will also be&#xD;
      recorded.&#xD;
&#xD;
      Induction and Maintenance of General Anesthesia:&#xD;
&#xD;
      All patients will receive general anesthesia using an endotracheal tube to facilitate&#xD;
      ventilatory support.&#xD;
&#xD;
      Induction of anesthesia will be performed using the following:&#xD;
&#xD;
      I.V. Sufentanil 0.1- 0.2 mcg/kg I.V. Lidocaine 1.5 mg/kg I.V. Propofol 2-3 mg/kg I.V.&#xD;
      Rocuronium 0.6 -1.2 mg/kg General anesthesia will be maintained using 0.5-2.5% sevoflurane in&#xD;
      an O2:air mixture.&#xD;
&#xD;
      Ventilatory settings will be the following:&#xD;
&#xD;
      6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (end-tidal C02) PEEP (positive&#xD;
      end-expiratory pressure) in order to ensure a driving pressure (P plateau- PEEP) below 15&#xD;
      mmHg Additional analgesia will be provided with I.V. Acetaminophen 15 mg/kg and I.V.&#xD;
      Diclofenac 1 mg/kg, I.V. Tramadol 1-2 mg/kg and, if necessary, additional boluses of I.V.&#xD;
      sufentanil 5 mcg.&#xD;
&#xD;
      If muscle relaxation is required by the surgeon, I.V. rocuronium may be administered in 10-20&#xD;
      mg boluses. I.V. Sugammadex 4 mg/kg will be administered if needed to reverse neuromuscular&#xD;
      blockade.&#xD;
&#xD;
      Upon emergence from anesthesia:&#xD;
&#xD;
      All patients will be transferred to the post-operative recovery unit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients will be blinded to the group, as well as the outcomes assessor and the investigator.&#xD;
The anesthesiologist responsible for the patient's anesthesia will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>T-MOCA-baseline</measure>
    <time_frame>12 hours</time_frame>
    <description>In order to evaluate perioperative neurocognitive disorders, patients will take the T-MOCA test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T-MOCA-6-weeks-postoperatively</measure>
    <time_frame>6 weeks</time_frame>
    <description>In order to evaluate perioperative neurocognitive disorders, patients will take the T-MOCA test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T-MOCA-3-months-postoperatively</measure>
    <time_frame>3 months</time_frame>
    <description>In order to evaluate perioperative neurocognitive disorders, patients will take the T-MOCA test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of patient's baseline pre-operative peripheral IL-6</measure>
    <time_frame>12 hours</time_frame>
    <description>Blood samples to measure IL-6 will be drawn prior to the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of patient's post-operative peripheral IL-6; 6 hours post-operative</measure>
    <time_frame>24 hours</time_frame>
    <description>Blood samples to measure IL-6 will be drawn 6 hours after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of patient's post-operative peripheral IL-6 ; 24 hours post-operative</measure>
    <time_frame>24 hours</time_frame>
    <description>Blood samples to measure IL-6 will be drawn 24 hours after the surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Hyperventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventilatory settings will be the following:&#xD;
6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (&lt;35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoventilation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ventilatory settings will be the following:&#xD;
6-8 ml/kg and Respiratory rate adjusted to the required ETC02 ( 40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperventilation</intervention_name>
    <description>Ventilatory settings will be the following:&#xD;
6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (&lt;35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg.</description>
    <arm_group_label>Hyperventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoventilation</intervention_name>
    <description>Ventilatory settings will be the following:&#xD;
6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg.</description>
    <arm_group_label>Hypoventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with an ASA (American Society of Anesthesia) score of I- III&#xD;
&#xD;
          -  Scheduled for total hip arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lack of local language comprehension&#xD;
&#xD;
          -  neuropsychiatric disturbance&#xD;
&#xD;
          -  history of drug/alcohol abuse&#xD;
&#xD;
          -  use of anticholinergic drugs, benzodiazepines, opiates/neuroleptic drugs&#xD;
&#xD;
          -  patients with an infectious disease within the last month/immune-suppressant therapy&#xD;
             within the last 2 months (e.g., azathioprine or cyclosporine) or chronic medication&#xD;
             with potential immune-modulatory effects&#xD;
&#xD;
          -  patients who underwent major surgery within the last 3 months&#xD;
&#xD;
          -  Patients with cardiovascular, or respiratory diseases (including smoking) resulting in&#xD;
             clinically relevant impaired function&#xD;
&#xD;
          -  Patients with pre-existing CVA, dementia, and other neurological conditions that would&#xD;
             interfere with their ability to participate cognitively&#xD;
&#xD;
          -  patients with active malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Saxena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Charleroi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Saxena, MD</last_name>
    <phone>+3271923380</phone>
    <email>sarah.saxena@ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Boogaerts, MD; PhD</last_name>
    <phone>+3271923380</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU-Charleroi Hopital Civil Marie Curie</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Saxena, MD</last_name>
      <email>sarah.saxena@ulb.ac.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Libre de Bruxelles</investigator_affiliation>
    <investigator_full_name>Sarah Saxena</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

